Sarepta slumps as gene therapy setback adds to drug pipeline woes
                    
                        (Reuters) -Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline. The latest setback comes after Sarepta's...                    
                    
                        
                        
                            Reuters